GSK-690693 (GSK690693)是一种ATP竞争型的泛Akt抑制剂，在无细胞试验中对Akt1/2/3的IC₅₀分别为2 nM、13 nM、9 nM，具有潜在的抗癌活性。GSK-690693也抑制AGC激酶家族成员：PKA (IC₅₀: 24 nM)、PrkX (IC₅₀: 5 nM)和PKC (IC₅₀: 2-21 nM)。此外，GSK-690693也能抑制AMPK和DAPK3，IC₅₀值分别为50 nM和81 nM。

参考文献

1. Rhodes N, et al. Characterization of an Akt kinase inhibitor with potent pharmacodynamic and antitumor activity. Cancer Res. 2008 Apr 1;68(7):2366-74.
2. Levy DS, et al. AKT inhibitor, GSK690693, induces growth inhibition and apoptosis in acute lymphoblastic leukemia cell lines. Blood. 2009 Feb 19;113(8):1723-9.
3. Altomare DA, et al. GSK690693 delays tumor onset and progression in genetically defined mouse models expressing activated Akt. Clin Cancer Res. 2010 Jan 15;16(2):486-96.
4. Konno H, et al. Pro-inflammation Associated with a Gain-of-Function Mutation (R284S) in the Innate Immune Sensor STING. Cell Rep. 2018 Apr 24;23(4):1112-1123.

冰袋运输。粉末直接保存于-20℃，有效期2年。建议分装后-20℃干燥保存，避免反复冻融。